Aligos Therapeutics Form 4 / Leonid Beigelman ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Beigelman Leonid

(Last)

(First)

(Middle)

C/O ALIGOS THERAPEUTICS, INC.

1 CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
President

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								1,026,991	D
Common Stock								69,744	I	See footnote⁽¹⁾
Common Stock								69,744	I	See footnote⁽²⁾
Common Stock								35,408	I	See footnote⁽³⁾
Common Stock								35,408	I	See footnote⁽⁴⁾
Common Stock	10/20/2020		C		163,842	A	⁽⁵⁾	163,842	I	See footnote⁽⁶⁾
Common Stock	10/20/2020		C		13,559	A	⁽⁵⁾	13,559	I	See footnote⁽⁷⁾
Common Stock	10/20/2020		C		13,559	A	⁽⁵⁾	13,559	I	See footnote⁽⁸⁾
Common Stock	10/20/2020		C		50,781	A	⁽⁵⁾	214,623	I	See footnote⁽⁶⁾
Common Stock	10/20/2020		C		3,359	A	⁽⁵⁾	16,918	I	See footnote⁽⁷⁾
Common Stock	10/20/2020		C		3,359	A	⁽⁵⁾	16,918	I	See footnote⁽⁸⁾
Common Stock	10/20/2020		C		21,724	A	⁽⁵⁾	236,347	I	See footnote⁽⁶⁾
Common Stock	10/20/2020		C		1,437	A	⁽⁵⁾	18,355	I	See footnote⁽⁷⁾
Common Stock	10/20/2020		C		1,437	A	⁽⁵⁾	18,355	I	See footnote⁽⁸⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series A Preferred Stock	⁽⁵⁾	10/20/2020		C			163,842	⁽⁵⁾	⁽⁵⁾	Common Stock	163,842	$0.00	0	I	See footnote⁽⁶⁾
Series A Preferred Stock	⁽⁵⁾	10/20/2020		C			13,559	⁽⁵⁾	⁽⁵⁾	Common Stock	13,559	$0.00	0	I	See footnote⁽⁷⁾
Series A Preferred Stock	⁽⁵⁾	10/20/2020		C			13,559	⁽⁵⁾	⁽⁵⁾	Common Stock	13,559	$0.00	0	I	See footnote⁽⁸⁾
Series B-1 Preferred Stock	⁽⁵⁾	10/20/2020		C			50,781	⁽⁵⁾	⁽⁵⁾	Common Stock	50,781	$0.00	0	I	See footnote⁽⁶⁾
Series B-1 Preferred Stock	⁽⁵⁾	10/20/2020		C			3,359	⁽⁵⁾	⁽⁵⁾	Common Stock	3,359	$0.00	0	I	See footnote⁽⁷⁾
Series B-1 Preferred Stock	⁽⁵⁾	10/20/2020		C			3,359	⁽⁵⁾	⁽⁵⁾	Common Stock	3,359	$0.00	0	I	See footnote⁽⁸⁾
Series B-2 Preferred Stock	⁽⁵⁾	10/20/2020		C			21,724	⁽⁵⁾	⁽⁵⁾	Common Stock	21,724	$0.00	0	I	See footnote⁽⁶⁾
Series B-2 Preferred Stock	⁽⁵⁾	10/20/2020		C			1,437	⁽⁵⁾	⁽⁵⁾	Common Stock	1,437	$0.00	0	I	See footnote⁽⁷⁾
Series B-2 Preferred Stock	⁽⁵⁾	10/20/2020		C			1,437	⁽⁵⁾	⁽⁵⁾	Common Stock	1,437	$0.00	0	I	See footnote⁽⁸⁾

Explanation of Responses:

1. Leonid Beigelman and Natalia Lozovsky, Trustees, or their successors in trust, under the Beigelman 2020 Grantor Retained Annuity Trust dated June 25, 2020.

2. Natalia Lozovsky and Leonid Beigelman, Trustees, or their successors in trust, under the Lozovsky 2020 Grantor Retained Annuity Trust dated June 25, 2020.

3. Leonid Beigelman and Natalia Lozovsky, Trustees, or their successors in trust, under the Dina Beigelman 2020 Irrevocable Trust, dated July 02, 2020.

4. Leonid Beigelman and Natalia Lozovsky, Trustees, or their successors in trust, under the Victor Beigelman 2020 Irrevocable Trust, dated July 02, 2020.

5. Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

6. Beigelman and Lozovsky Living Trust.

7. Dina Beigelman Irrevocable Trust.

8. Victor Beigelman Irrevocable Trust.

	/s/ Lucinda Y. Quan, as attorney-in fact for Leonid Beigelman	10/20/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Aligos Therapeutics (ALGS) Form 4Aligos Therapeutics / Leonid Beigelman ownership change